Drug Trial Radar · NCT06345729
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
348
Planned (sponsor's estimate)
Start
May 24, 2024
Primary completion
Jan 24, 2028
Study completion Feb 18, 2031
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Apr 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. There is one primary study hypothesis: Combination of calderasib and pembrolizumab is superior to placebo plus pembrolizumab with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
Conditions
- Non-small Cell Lung Cancer
Interventions
CalderasibDrug
Oral tablets
PlaceboOther
Oral tablets
PembrolizumabBiological
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: Up to approximately 42 months
Locations
248 sites in 30 countries. Site status is shown where the registry gives one.
CBCC Global Research, Inc. ( Site 0123)
Bakersfield, California · Recruiting
Beverly Hills Cancer Center ( Site 0116)
Beverly Hills, California · Recruiting
Stamford Hospital ( Site 0136)
Stamford, Connecticut · Recruiting
Mount Sinai Cancer Center ( Site 0137)
Miami Beach, Florida · Completed
Orchard Healthcare Research Inc. ( Site 0115)
Skokie, Illinois · Recruiting
Truman Medical Center ( Site 0126)
Kansas City, Missouri · Recruiting
Cox Medical Center North ( Site 0133)
Springfield, Missouri · Recruiting
St. Vincent Frontier Cancer Center-Research ( Site 0105)
Billings, Montana · Recruiting
Atlantic Health System Morristown Medical Center ( Site 0121)
Morristown, New Jersey · Completed
New York Oncology Hematology, P.C. ( Site 0132)
Albany, New York · Recruiting
University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0103)
Cincinnati, Ohio · Recruiting
Kettering Health Main Campus-Kettering Health Cancer Center ( Site 0106)
Kettering, Ohio · Completed
Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0134)
Lancaster, Pennsylvania · Recruiting
Oncology Consultants P.A. ( Site 0113)
Houston, Texas · Recruiting
Circuit Clinical/SSM Health Dean Medical Group ( Site 0129)
Madison, Wisconsin · Recruiting
Centro de Oncología e Investigación de Buenos Aires ( Site 0308)
Berazategui, Buenos Aires, Argentina · Recruiting
AUSTRAL MEDICAL CENTER ( Site 0302)
CABA, Buenos Aires, Argentina · Completed
Centro Oncologico Korben ( Site 0304)
CABA, Buenos Aires, Argentina · Recruiting
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0300)
Mar del Plata, Buenos Aires, Argentina · Recruiting
Clinica Viedma S. A ( Site 0307)
Viedma, Río Negro Province, Argentina · Recruiting
Fundacion Estudios Clinicos ( Site 0306)
Rosario, Santa Fe Province, Argentina · Recruiting
Sanatorio Parque ( Site 0301)
Rosario, Santa Fe Province, Argentina · Recruiting
Chris O'Brien Lifehouse ( Site 3000)
Camperdown, New South Wales, Australia · Recruiting
Cancer Care Service Hervey Bay ( Site 3003)
Urraween, Queensland, Australia · Recruiting
Frankston Hospital ( Site 3002)
Frankston, Victoria, Australia · Recruiting
One Clinical Research ( Site 3001)
Nedlands, Western Australia, Australia · Recruiting
Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 2400)
Vienna, Austria · Recruiting
Medizinische Universität Graz-Klinische Abteilung für Pulmonologie ( Site 2401)
Graz, Styria, Austria · Recruiting
Instituto Nacional de Câncer - INCA ( Site 0446)
Rio de Janeiro, Brazil · Recruiting
Americas ( Site 0431)
Rio de Janeiro, Brazil · Recruiting
Hospital Mario Penna ( Site 0436)
Belo Horizonte, Minas Gerais, Brazil · Recruiting
Hospital de Câncer de Recife ( Site 0447)
Recife, Pernambuco, Brazil · Recruiting
Oncoclínica Oncologistas Associados ( Site 0441)
Teresina, Piauí, Brazil · Completed
Liga Norte Riograndense Contra o Câncer ( Site 0439)
Natal, Rio Grande do Norte, Brazil · Recruiting
Hospital de Caridade de Ijuí ( Site 0438)
Ijuí, Rio Grande do Sul, Brazil · Recruiting
Hospital de Clínicas de Passo Fundo ( Site 0442)
Passo Fundo, Rio Grande do Sul, Brazil · Recruiting
Irmandade da Santa Casa de Misericórdia de Porto Alegre-Centro Multidisciplinar de Pesquisa Clínica ( Site 0435)
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Fundação Pio XII - Hospital de Câncer de Barretos-Unidade de Pesquisa Clínica ( Site 0437)
Barretos, São Paulo, Brazil · Recruiting
MHAT - Heart and Brain ( Site 1006)
Pleven, Bulgaria · Recruiting
Medical Center Futuremeds ( Site 1007)
Plovdiv, Bulgaria · Recruiting
Showing 40 of 248 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.